Melphalan Sun

Melphalan, the active ingredient in Melphalan Sun, is an alkylating agent presented as an injectable solution for intravenous use. It is employed in the treatment of certain hematologic and solid tumors, including multiple myeloma, ovarian cancer and malignant melanoma, in adult patients.

GNH USA supplies Melphalan Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product meets European Union quality standards and is manufactured under GMP conditions.

Melphalan is used as an antineoplastic agent that interferes with DNA replication in malignant cells. - Multiple myeloma: helps to reduce tumor burden and prolong survival. - Ovarian cancer: used in combination regimens to improve response rates. - Malignant melanoma: administered as part of high‑dose protocols for advanced disease.

Melphalan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: typical gastrointestinal upset during treatment. - Myelosuppression: reduced white blood cells, red blood cells, and platelets. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Fatigue: generalized tiredness often reported by patients. - Alopecia: temporary hair loss during therapy.

Serious or Rare Side Effects: - Secondary malignancies: risk of developing new cancers later. - Severe infection: due to profound neutropenia. - Pulmonary fibrosis: rare lung scarring. - Renal toxicity: impaired kidney function in high‑dose regimens. - Cardiotoxicity: uncommon heart rhythm disturbances.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor laboratory parameters. - Baseline blood counts: obtain complete blood count and differential. - Renal function: assess serum creatinine and glomerular filtration rate. - Hepatic function: check liver enzymes and bilirubin levels. - Pregnancy status: avoid use in pregnant or nursing women unless benefits outweigh risks. - Concomitant medications: review for potential interactions that may increase toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with other agents that affect bone marrow or renal clearance.

Major Interactions (Avoid): - High‑dose cyclophosphamide: additive myelosuppression. - Nephrotoxic antibiotics (e.g., aminoglycosides): increased renal toxicity. - Live vaccines: risk of uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antifungal azoles: may alter melphalan metabolism. - Allopurinol: can increase hematologic toxicity. - NSAIDs: may exacerbate renal impairment.